Clovis Oncology is Pharmaceuticals in United States that focus on Clovis Oncology Inc business. Founded in 2009. They cover business area such as Clovis Oncology Inc, innovative anti-cancer agent, additional international market, its development program, specific subset, cancer population, its product candidate, Rucaparib, Lucitanib, an oral small molecule inhibitor, two indication, fallopian tube, primary peritoneal cancer, Nivolumab Combo.
2009
( 15 years old in 2024 )
Clovis Oncology Inc
-
5500 Flatiron Parkway
Boulder, CO 80301
United States
Private
Clovis Oncology Incinnovative anti-cancer agentadditional international marketits development programspecific subsetcancer populationits product candidateRucaparibLucitaniban oral small molecule inhibitortwo indicationfallopian tubeprimary peritoneal cancerNivolumab Combo
* We use standard office opening hours in near Clovis Oncology's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Clovis Oncology is Pharmaceuticals business from United States that founded in 2009 (15 years old in 2024), Clovis Oncology business is focusing on Clovis Oncology Inc.
Clovis Oncology headquarter office and corporate office address is located in 5500 Flatiron Parkway Boulder, CO 80301 United States.
Clovis Oncology was founded in United States.
In 2024, Clovis Oncology is currently focus on Clovis Oncology Inc sector.
Above is snippet of Google Trends for "Clovis Oncology Inc" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Clovis Oncology, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
